80.52 0.00 (0.00%)
After hours: 4:34PM EDT
|Bid||80.55 x 100|
|Ask||81.68 x 1500|
|Day's range||79.00 - 81.70|
|52-week range||28.14 - 84.37|
|PE ratio (TTM)||N/A|
|Earnings date||25 Apr 2018 - 30 Apr 2018|
|Forward dividend & yield||N/A (N/A)|
|1y target est||85.53|
The development, which follows a partial clinical hold on the same product last year, raises ‘multiple concerns,’ J.P. Morgan analysts said.
Sarepta extended its lead in Duchenne muscular dystrophy on Thursday as new rival Solid Biosciences cratered after the FDA placed its trial on a clinical hold.
Shares of Sarepta Therapeutics (SRPT) are higher on Thursday, after rival Solid Biosciences' (SLDB) microdystrophin gene transfer program for Duchenne muscular dystrophy (DMD), was put on clinical hold. Solid Biosciences had to pause its IGNITE DMD clinical trial on safety concerns, after the first patient who received the gene therapy about a month ago was hospitalized due an unexpected event, including a reduced red-blood-cell count. Although the patient is recovering, Solid Biosciences reported the incident, given that it was unexpected, leading to the hold. W.C. Wainwright's Debjit Chattopadhyay reiterated a Buy rating and $92 price target on Sarepta today, writing that given the differences in the drugs and their evolving safety profiles, Solid Biosciences's setback looks like good news for Sarepta, which investors should buy "in the event of any collateral damage stemming from the Solid Biosciences clinical hold." He argues that the news will fortify the perception that Solid Biosciences' offering is a "potentially risky alternative" to Sarepta's competing investigational drug, and it may make it harder for Solid Biosciences to enroll patients in trials, especially if Sarepta continues to report positive news.
Shares of Solid Biosciences (SLDB) were hit after the FDA put a clinical hold on a phase III study of lead DMD candidate, SGT-001.
The biotech sector was in focus last week with key news - Orexigen going bankrupt, Biogen acquires asset from Pfizer, Regeneron cuts Praluent price among others.
Sarepta (SRPT) will file a rolling NDA for its second DMD drug, golodirsen. The submission is expected to be completed in late 2018.
Zacks Investment Ideas feature highlights: Sarepta Therapeutics, bluebird bio, Editas Medicine, Align Technology and Intellia Therapeutics
Sarepta touched a 16-year high on the likelihood a muscular dystrophy drug could gain approval two years ahead of schedule.
Shares of Sarepta Therapeutics Inc. surged 4.9% in premarket trade Monday, after the biopharmaceutical company said it planned to submit a New Drug Application (NDA) for its Duchenne muscular dystrophy ...
Sarepta Therapeutics says regulators at the Food and Drug Administration have told it they were open to reviewing its next experimental treatment for Duchenne muscular dystrophy, meaning that it could file an application for the new medicine by the end of this year.
•...examine the arguments for and against Dollar Tree. The S&P 500 is little changed at 2727.76 at 12:44 p.m. today, while the Dow Jones Industrial Average has declined 45.99 points, or 0.2%, to 24,755.37.
Sarepta (SRPT) beats earnings estimates while missing revenues in the fourth quarter of 2017, based on strong sales of Exondys 51.
On a per-share basis, the Cambridge, Massachusetts-based company said it had a loss of 37 cents. The results did not meet Wall Street expectations. The average estimate of seven analysts surveyed by Zacks ...
Sarepta Therapeutics Inc. shares dropped 1.8% after the bell on Thursday after the company reported fourth-quarter profit and revenue beats. The company reported a loss of $24 million, or a loss of 37 ...
Sarepta Therapeutics (SRPT) is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat.
Sarepta Therapeutics Inc. shares dropped 6% in extremely heavy morning trade Friday after a report by new analysis service EP Vantage said that the biotech had halted treatment at United Kingdom sites ...
A biotech investor shares a few reflections on adaptive ski coaching: By bringing together his passion for the mountains with his profession as an investor in biomedical therapies, adaptive coaching completes the circle by focusing on the most important of life’s elements — the human element.
Shares of gene therapy companies fell sharply Tuesday, after a report by a prominent scientist revealed the safety concerns that led him to resign recently from Solid Biosciences Inc.’s scientific advisory ...
Shares of AveXis and Solid Biosciences have been depressed in morning trading after the publication of an article in the medical journal Human Gene Therapy about severe toxicity in two animal species from administration of a gene therapy similar to one used by AveXis for spinal muscular atrophy, or SMA. The article was co-authored by James Wilson, director of gene therapy in the Department of Medicine at the University of Pennsylvania, who stepped down from Solid’s scientific advisory board shortly before the company’s recent initial public offering. Shares of AveXis (AVXS), a leader in gene therapy, are off $2.53, or 2%, to around $120 after touching a low of $110 earlier in the session.
Solid Biosciences (SLDB) pulled off its IPO late Thursday but had to price the deal below its most recent pricing range after the company made a surprise disclosure early Thursday about a partial clinical hold involving its critical clinical trial for a gene therapy treatment for Duchenne muscular dystrophy (DMD). In its amended IPO prospectus Thursday, Solid stated the Food and Drug Administration won’t allow the company to treat patients in its initial phase 1/2 clinical trial with a high dose of the gene therapy until it resolves certain manufacturing issues. The company, in the amended filing, downplayed the development, saying that it plans to address the manufacturing issues raised by the FDA and that it doesn’t expect the “overall timing for clinical development of SGT-001 will be affected by the partial clinical hold.” SGT-001 is the DMD gene therapy.